TY  - JOUR
AU  - Weiss, Sarah A
AU  - Sznol, Mario
AU  - Shaheen, Montaser
AU  - Berciano-Guerrero, Miguel-Angel
AU  - Muñoz-Couselo, Eva
AU  - Rodriguez-Abreu, Delvys
AU  - Boni, Valentina
AU  - Schuchter, Lynn M
AU  - Gonzalez-Cao, Maria
AU  - Arance, Ana
AU  - Wei, Wei
AU  - Ganti, Apar Kishor
AU  - Hauke, Ralph J
AU  - Berrocal, Alfonso
AU  - Iannotti, Nicholas O
AU  - Hsu, Frank J
AU  - Kluger, Harriet M
PY  - 2023
DO  - 10.1158/1078-0432.CCR-23-0475
SN  - 1557-3265
UR  - https://hdl.handle.net/10668/28504
T2  - Clinical Cancer Research
AB  - Purpose: Disease progression during or after anti-PD-1-based treatment is common in advanced melanoma. Sotigalimab is a CD40 agonist antibody with a unique epitope specificity and Fc receptor binding profile optimized for activation of CD40-expressing...
LA  - en
PB  - American Association for Cancer Research
KW  - Nivolumab
KW  - Melanoma
KW  - Sotigalimab
KW  - Immune Checkpoint Inhibitors
KW  - Asthenia
KW  - Myalgia
KW  - Fatigue
KW  - Disease Progression
KW  - Nausea
KW  - Headache
TI  - A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy.
TY  - research article
VL  - 30
ER  -